Overview

Comparing Chemoprevention Approaches for School-based Malaria Control

Status:
Enrolling by invitation
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an individually randomized, controlled, single blind three arm clinical trial of malaria chemoprevention strategies Arm 1: Intermittent screening and treatment (IST) - students will receive treatment if they have a positive high sensitivity rapid diagnostic test (RDT). Arm 2: Intermittent preventive treatment (IPT) - all students will receive treatment. Arm 3: Control - students will receive standard of care (no preventive treatment). Outcomes include P. falciparum infection and parasite density, gametocyte carriage and gametocyte density, anemia, cognitive function and educational testing, as well as infection prevalence in student's households to assess the impact on transmission.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland, Baltimore
Collaborators:
Doris Duke Charitable Foundation
Kamuzu University of Health Sciences
Treatments:
Artenimol
Chloroquine
Piperaquine